Characterization of human tumor cell lines transduced with the cDNA encoding either tumor necrosis factor α (TNF-a) or interleukin-2 (IL-2)

Yannelli, John R.; Hyatt, Cornelia; Johnson, Susan E.; Hwu, Patrick; Rosenberg, Steven A.

doi:10.1016/0022-1759(93)90199-h

Cited by 39 publications

(16 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…[9][10][11]14,[29][30][31][32][33] It is unknown, however, whether the maximal tumor-specific T-cell response is achieved by living tumor cells or by cell vaccines inactivated through irradiation or freeze/thaw treatment. Here, we show that living tumor cells and tumor cells inactivated by irradiation induce similar T-cell effector responses, i.e., T-cell proliferation, inhibition of AICD and tumor cell lysis.…”

Section: Discussionmentioning

confidence: 99%

Necrotic death but not irradiation abolishes costimulation of T‐cell effector functions and survival by CD80‐expressing tumor cells

Stärck

Schölz

Blankenstein

et al. 2005

Intl Journal of Cancer

View full text Add to dashboard Cite

Tumor vaccination by the use of gene‐modified cancer cells that provide costimulatory signals has been successfully applied in preclinical animal models and is currently evaluated in a variety of clinical settings. In previous work, we demonstrated the efficacy of B7.1/CD80 to promote tumor immunity in syngeneic murine models and to prevent deletion of activated T cells by activation‐induced cell death (AICD). In clinical trials, tumor cell vaccines are generally inactivated to avoid transfer of live tumor cells, i.e., additional tumor burden. Previous data indicated, however, that inactivation of tumor cells by lethal ionizing irradiation abrogates tumor vaccination by CD80‐expressing cells. Here, we compare living and irradiated allogeneic tumor cells regarding their capacity to induce T‐cell effector functions and their propensity to interfere with T‐cell deletion by apoptosis. Both lethally irradiated and nonirradiated tumor cells facilitated T‐cell proliferation, tumor cell lysis, and interfered with T‐cell AICD to a similar extent. In contrast, necrotic tumor cells failed to costimulate T‐cell effector functions. Thus, irradiation does not seem to hamper tumor cell‐mediated costimulation of T‐cell effector functions. In contrast, necrosis of gene‐modified tumor cells abrogates costimulation of T cells by CD80‐expressing cells. © 2005 Wiley‐Liss, Inc.

show abstract

Section: Discussionmentioning

confidence: 99%

Necrotic death but not irradiation abolishes costimulation of T‐cell effector functions and survival by CD80‐expressing tumor cells

Stärck

Schölz

Blankenstein

et al. 2005

Intl Journal of Cancer

View full text Add to dashboard Cite

show abstract

“…43 Recientemente se obtuvieron resultados exitosos contra el melanoma metastásico en seres humanos mediante linfocitos genéticamente modificados para atacarlo. 44 También se ha introducido el gen del factor de necrosis tumoral (TNF, por su sigla en inglés) en LIT, de forma tal que, al dirigirse hacia el tumor, éste sea destruido.…”

Section: Aumento De La Actividad Antitumoral De Células Del Sistema Iunclassified

Terapia génica: opción terapéutica para neoplasias, infecciones y enfermedades monogénicas

Cavagnari

2011

Arch Argent Pediat

View full text Add to dashboard Cite

Arch Argent Pediatr 2011;109(4):326-332 / 326 RESUMEN Durante las últimas dos décadas, los resultados de varios protocolos de terapia génica llevaron al descreimiento de la comunidad médica. Sin embargo, en años recientes se obtuvieron resultados muy exitosos que la reposicionaron como una opción prometedora para el tratamiento de muchas enfermedades. Frente a este resurgimiento del interés de la comunidad científica internacional en la terapia génica, resulta apropiado que el médico generalista comprenda sus fortalezas y limitaciones. El objetivo de este artículo es comentar la forma en que la terapia génica encara actualmente el tratamiento de patologías tan diversas como neoplasias, infecciones y enfermedades monogénicas.

show abstract

“…The samples were minced to 3-mm 3 chunks and enzyme digested at 37˚C (5% CO 2 in air environment) to single cell suspensions as previously described (26). The diced tissue samples were mixed with enzyme medium (40 ml of enzyme medium per gram of tissue) (27) and placed in sterile bottles containing a magnetic stir bar for 12-18 h. The enzyme medium was comprised of RPMI-1640 (Gibco-BRL) supplemented with DNAse (30,000 units/ml), collagenase (1 g/l), hyaluronidase (100 mg/l), penicillin (50 μg/ml), streptomycin (50 μg/ml), amphotericin (50 μg/ml), and gentamycin sulfate (10 μg/ml). Following digestion, the samples were strained through a sterile 70-μm mesh filter to remove clumps of fibrous material, centrifuged to collect cells and washed with PBS containing 5% fetal bovine serum (FBS) to neutralize residual enzymes in the medium.…”

Section: Preparation Of Lung Tumors and Normal Adjacent Tissuementioning

confidence: 99%

Characteristics of PBMC obtained from leukapheresis products and tumor biopsies of patients with non-small cell lung cancer

Yannelli

Tucker²,

Hidalgo³

et al. 2009

Oncol Rep

View full text Add to dashboard Cite

Abstract. The current study characterized peripheral blood mononuclear cells (PBMC) obtained from leukapheresis products of patients with non-small cell lung cancer (NSCLC) for cytokine release, the ability to incorporate tritiated thymidine following stimulation using PHA as well as the levels of both CD4 and CD8 regulatory T cells (Tregs) as defined by FoxP3 expression. Results were compared to normal donor PBMC obtained from buffy coat products.

show abstract

Characterization of human tumor cell lines transduced with the cDNA encoding either tumor necrosis factor α (TNF-a) or interleukin-2 (IL-2)

Cited by 39 publications

References 21 publications

Necrotic death but not irradiation abolishes costimulation of T‐cell effector functions and survival by CD80‐expressing tumor cells

Necrotic death but not irradiation abolishes costimulation of T‐cell effector functions and survival by CD80‐expressing tumor cells

Terapia génica: opción terapéutica para neoplasias, infecciones y enfermedades monogénicas

Characteristics of PBMC obtained from leukapheresis products and tumor biopsies of patients with non-small cell lung cancer

Contact Info

Product

Resources

About